Global Meningococcal Vaccines Market Trends, Types and Applications with Forecast to 2022

on

The global Meningococcal Vaccines Market is expected to grow moderately over the forecast period. Meningococcal disease is a possibly lethal illness caused by a bacterium called Neisseria meningitides. This bacterium is recognized for causing serious infection in the meninges, which are thin layers of connective tissues adjoining the spinal cord and brain. This disease occurs at irregular intervals all over the world with seasonal variations. It accounts for a part of endemic bacterial meningitis that advances quickly causing death within 24 hours from the commencement of symptoms.


Common medical symptoms of meningococcal disease include bacteremia, pneumonia, and meningitis. Other less common symptoms are pericarditis or endocarditis, conjunctivitis, pharyngitis, cervicitis, myocarditis, arthritis, and urethritis. Symptoms related to this disease include neck stiffness, nausea, lethargy, petechial rashes, high fever, confusion, and vomiting. Meningococcal vaccines are used for curing meningitis caused by bacterium Neisseria meningitides. Formerly, there were no cautionary measures existing to avoid meningitis and nutrient supplements along with antibiotics were used for the treatment of this disease. These vaccines are also used for treating septicemia, pneumonia, meningitis, and meningococcemia. It can be categorized based on their immunologic reactivity. Presently, the global meningococcal vaccines are of four types which include bivalent (serogroup A and C), tetravalent (serogroup A, C, Y, and W-135), polysaccharide based, and trivalent (serogroup A, C, and W-135).
There is, presently, only a single vaccine available for sero group B in the U.S., even though it accounted for more than one-third of the diseases cases in the country. The components and nature of the vaccines are heat-stable, purified, lyophilized capsular polysaccharides derivative of the meningococci of the corresponding sero groups. The major factor driving the growth of global meningococcal vaccines market includes the growing occurrence of meningitis across the globe.
Growing awareness about the diseases and their vaccines is also driving the overall market. Other factors responsible for the growth of the market  include several public-private partnerships for carrying out research & development activities, manufacturing quality vaccines at affordable prices, and the presence of vaccines in a pipeline and their expected commercialization. Additionally, rising government interventions in refining healthcare infrastructure, numerous awareness programs, and incorporation of security guidelines concerning meningococcal vaccines are also projected to positively impact the global meningococcal vaccines market. The introduction of advanced serotype B vaccines from large global drug makers including Pfizer and Novartis further boosts the demand.
North America emerged as the regional leader of the global Meningococcal Vaccines market on account of rising government prevention & intervention programs, and research & development activities by numerous manufacturers. The increased awareness about the health care facilities is responsible for the growth in the region. The majority of the revenue was generated by the U.S. in North America. However, Asia-Pacific meningococcal vaccines market is projected to have the highest growth rate in the market over the next eight years. This high growth rate can be attributed to factors such as increased spending on health care and low manufacturing costs. China, India, and Japan are estimated to be the most rapidly growing meningococcal vaccines market in Asia-Pacific.
Some of the key meningococcal vaccines industry participants include Neuron Biotech, Pfizer Inc., Sanofi S.A., Biomed Pvt. Ltd., Serum Institute of India Ltd., Baxter International, Novartis International AG, JN-International Medical Corporation, and GlaxoSmithKline Plc. Novartis International AG, GSK Plc., and Sanofi S.A. together account for more than 90% of the global market. Presently, Pfizer is also working towards generating a vaccine named MnBrLP2086. This vaccine is under clinical trial phase III and has been granted the breakthrough therapy by FDA.

Comments

Post a Comment